Alan Saltiel received his AB in Zoology from Duke University in 1975 with Magna Cum Laude distinction, and his Ph.D. in Biochemistry from the University of North Carolina in 1980. From 1981-1984 he did postdoctoral training with Pedro Cuatrecasas at the Wellcome Research Laboratories in Research Triangle Park, NC, studying mechanisms of insulin action. In 1984 he moved to the Rockefeller University as Assistant Professor, continuing work on the molecular and cellular biology of the actions of insulin and growth factors.
In 1990 he joined Parke Davis Pharmaceutical Research as Director of the Department of Signal Transduction, and was later promoted to Distinguished Research Fellow and Senior Director of Cell Biology at Parke Davis. At Parke Davis he reported to president of R&D Pedro Cuatrecasas, was responsible for drug discovery activities in diabetes, obesity and cancer, and sat on the senior management team and research committee overseeing all R&D activities. In 2001, Dr. Saltiel moved to the newly created Life Sciences Institute of the University of Michigan as Professor of Medicine and Physiology. In 2002, he was named Director of the Institute, and John Jacob Abel Professor in the Life Sciences.
He has received numerous awards, including the Rosalyn Yalow Research and Development Award from the American Diabetes Association, the Hirschl Award, the John Jacob Abel and the Goodman and Gilman Awards from ASPET, was elected to honorary membership in the American Society of Clinical Investigation, and membership in the Institute of Medicine of the National Academy of Sciences. He has given many named lectures and organized numerous meetings and conferences, and served on a number of advisory panels, scientific boards and editorial boards, including the Journal of Biological Chemistry, Endocrinology, Diabetes, the Journal of Clinical Investigation, Cell Metabolism and others.
He has seventeen issued patents, and has published over 250 original papers. He was ranked number 18 among most highly cited authors in biology and biochemistry over the past ten years. He currently is a frequent consultant to the pharmaceutical and biotechnology industry, as well as to numerous investment groups.